Johnson & Johnson reports 94% success rate in trial of coronary artery device

What happened

Johnson & Johnson reported 30-day results from a 158-patient trial of its experimental Shockwave Javelin catheter for severely narrowed coronary arteries. The study recorded 93.6% technical success, 93.4% of patients free from major cardiovascular events, and serious imaging-detected complications in 1.3%.

Confirmed

Global impact / market context

If further evidence and regulatory review support the results, the catheter could give Johnson & Johnson a route into complex coronary procedures and broaden its cardiovascular device business. That could create future sales, but the trial alone does not show an advantage over existing treatments.

Analyst inference

The reported results concern a limited 30-day period and a study of 158 patients, so they do not establish longer-term outcomes or superiority. The catheter remains investigational in the U.S.; commercial use and revenue therefore depend on further evidence and regulatory clearance.

Confirmed

What to watch

1. Watch for longer-term follow-up from the FORWARD CAD study, including whether patients remain free from major heart events and whether serious complications emerge beyond 30 days. Analyst inference
2. Watch for U.S. regulatory steps for the investigational catheter; clearance would be needed before the company could market it for routine use there. Confirmed
3. Watch for comparative evidence against existing treatments, since the reported trial results do not establish that the catheter works better than other options. Confirmed

Evidence

• seekingalpha.com